Found: 1
Select item for more details and to access through your institution.
1003-P: Clinical Response (HbA<sub>1c</sub> ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA<sub>1c</sub> and Body Weight in the SUSTAIN Program.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1003-P
- By:
- Publication type:
- Article